Publisher: DelveInsight-
Allergic Rhinitis - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the Allergic Rhinitis Market Size was highest in the US among the 7MM, accounting for approximately USD 3,600 million which is further expected to increase by 2034. In 2023, the prevalence of Allergic rhinitis was highest in Japan among the 7MM, accounting for approximately 6 ... Read More
-
Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights: Irritable bowel syndrome is believed to be a multifactorial disease involving motility dysfunction, visceral hypersensitivity, psychiatric comorbidity, neuroendocrine dysfunction, genetics and epigenetics, diet, and immune activation. Approximately 32 million cases of irritable bowel ... Read More
-
Need some help finding the right information ?Verify before you buy
or call us
US toll free: 800.298.5699
Worldwide: +1.240.747.3093
-
WHIM Syndrome - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights WHIM syndrome is a rare genetic disorder caused by CXCR4 mutations, leading to immunodeficiency, warts, hypogammaglobulinemia, and myelokathexis. In 2023, the diagnosed prevalent population in the 7MM was estimated to be around 179 individuals. WHIM is a significant health issue in th ... Read More
-
Post-Bariatric Hypoglycemia - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the United States accounted for approximately 90% of the total Post-Bariatric hypoglycemia market size within the seven major markets. Post-Bariatric hypoglycemia is the development of hypoglycemia (low blood sugar) following bariatric surgery, such as gastric bypass or sleev ... Read More
-
11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor - Pipeline Insight, 2025
DelveInsight’s, “11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 6+ pipeline drugs in 11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor pipeline landscape. It covers the pipeline drug profiles, inc ... Read More
-
1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025
“1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 1,3-Beta-Glucan Synthase Inhibitor development. The report provides detailed coverage of the pipeli ... Read More
-
5-HT1B Agonists - Pipeline Insight, 2025
DelveInsight’s, “5-HT1B Agonists - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in 5-HT1B Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics ... Read More
-
5-HT4 Agonist - Pipeline Insight, 2025
“5-HT4 Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT4 Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, ... Read More
-
Adenosine A1 Receptor Agonist - Pipeline Insight, 2025
“Adenosine A1 Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A1 Receptor Agonist development. The report provides detailed coverage of the pipeline landsca ... Read More
-
Adenosine A3 Receptor Antagonist - Pipeline Insight, 2025
“Adenosine A3 Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A3 Receptor Antagonist development. The report provides detailed coverage of the pipeline l ... Read More
-
Adenosine A2A Receptor Antagonist - Pipeline Insight, 2025
“Adenosine A2A Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A2A Receptor Antagonist development. The report provides detailed coverage of the pipeline ... Read More
-
Alpha Receptor Antagonist - Pipeline Insight, 2025
“Alpha Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for t ... Read More
-
Alpha-2 Antagonist - Pipeline Insight, 2025
“Alpha-2 Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha-2 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism ... Read More
-
Amyloid Protein Blockers - Pipeline Insight, 2025
“Amyloid Protein Blockers - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Amyloid Protein Blockers development. The report provides detailed coverage of the pipeline landscape for thi ... Read More
-
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2025
DelveInsight’s, “Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles ... Read More
-
Angiopoietin Inhibitor - Pipeline Insight, 2025
“Angiopoietin Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angiopoietin Inhibitor development. The report provides detailed coverage of the pipeline landscape for this me ... Read More
-
Anti GM-CSF Antibody - Pipeline Insight, 2025
“Anti GM-CSF Antibody - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti GM-CSF Antibody development. The report provides detailed coverage of the pipeline landscape for this mechan ... Read More
-
Anti-CD28 Antibody - Pipeline Insight, 2025
“Anti-CD28 Antibody - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD28 Antibody development. The report provides detailed coverage of the pipeline landscape for this mechanism ... Read More
-
Beta Receptor Agonist - Pipeline Insight, 2025
“Beta Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Beta Receptor Agonist development. The report provides detailed coverage of the pipeline landscape for this mech ... Read More
-
Beta-2 Receptors Antagonist - Pipeline Insight, 2025
“Beta-2 Receptors Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Beta-2 Receptors Antagonist development. The report provides detailed coverage of the pipeline landscape f ... Read More
-
Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2025
DelveInsight’s, “Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Cannabinoid Receptor Type 1 (CB1) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and no ... Read More
-
Cannabinoid Agonist - Pipeline Insight, 2025
DelveInsight’s, “Cannabinoid Agonist - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Cannabinoid Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the the ... Read More
-
Cathepsin S inhibitor - Pipeline Insight, 2025
“Cathepsin S inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cathepsin S inhibitor development. The report provides detailed coverage of the pipeline landscape for this mech ... Read More
-
CCR4 Inhibitor - Pipeline Insight, 2025
“CCR4 Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across CCR4 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of actio ... Read More
-
CCR3 Inhibitor - Pipeline Insight, 2025
“CCR3 Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across CCR3 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of actio ... Read More
Research Assistance